Bank of New York Mellon Corp Sells 46,291 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Posted by Francis Steltz on Aug 1st, 2026

Bank of New York Mellon Corp trimmed its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 11.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 358,719 shares of the company’s stock after selling 46,291 shares during the period. Bank of New York Mellon Corp’s holdings in Crinetics Pharmaceuticals were worth $13,029,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its stake in shares of Crinetics Pharmaceuticals by 107.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 639 shares of the company’s stock worth $30,000 after buying an additional 331 shares during the last quarter. Headlands Technologies LLC purchased a new position in Crinetics Pharmaceuticals during the second quarter valued at $30,000. Raymond James Financial Inc. purchased a new position in Crinetics Pharmaceuticals during the second quarter valued at $45,000. Parallel Advisors LLC boosted its holdings in Crinetics Pharmaceuticals by 34.6% in the fourth quarter. Parallel Advisors LLC now owns 1,225 shares of the company’s stock worth $57,000 after acquiring an additional 315 shares in the last quarter. Finally, Arax Advisory Partners boosted its holdings in Crinetics Pharmaceuticals by 131.2% in the fourth quarter. Arax Advisory Partners now owns 1,498 shares of the company’s stock worth $70,000 after acquiring an additional 850 shares in the last quarter. 98.51% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CRNX. Jefferies Financial Group downgraded Crinetics Pharmaceuticals from a “buy” rating to a “hold” rating and raised their price target for the company from $55.00 to $85.00 in a report on Tuesday, July 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research note on Friday, July 17th. Lifesci Capital downgraded shares of Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Piper Sandler lowered shares of Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, JonesTrading cut shares of Crinetics Pharmaceuticals from a “buy” rating to a “hold” rating and set a $85.00 target price for the company. in a report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $81.00.

Read Our Latest Stock Report on CRNX

Crinetics Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ CRNX opened at $83.52 on Friday. The firm’s 50-day moving average price is $54.15 and its 200-day moving average price is $46.24. Crinetics Pharmaceuticals, Inc. has a 52-week low of $25.83 and a 52-week high of $84.00. The company has a market cap of $8.81 billion, a PE ratio of -16.28 and a beta of 0.23.

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.01). The company had revenue of $10.73 million for the quarter, compared to analysts’ expectations of $8.51 million. Crinetics Pharmaceuticals had a negative net margin of 2,747.18% and a negative return on equity of 43.96%. The firm’s revenue for the quarter was up 2873.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.04) earnings per share. As a group, equities research analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -4.86 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Coelho Rogerio Vivaldi sold 3,000 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $40.00, for a total value of $120,000.00. Following the transaction, the director directly owned 19,225 shares in the company, valued at $769,000. This trade represents a 13.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephanie Okey sold 6,900 shares of Crinetics Pharmaceuticals stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $35.67, for a total value of $246,123.00. Following the completion of the sale, the director directly owned 6,400 shares of the company’s stock, valued at $228,288. The trade was a 51.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.80% of the company’s stock.

Crinetics Pharmaceuticals Profile

(Free Report)

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.